Aprepitant to Improve Same Day Discharge for TKA

Phase 4 Not yet recruiting 350 enrolled Endeavor Health Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.) · collab

RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this research is to study whether adding an FDA approved medication called aprepitant (a medication given to patients like you to reduce or eliminate nausea and vomiting) to the usual treatment to prevent nausea and vomiting given to patients during knee replacement surgery helps more patients go home on the same day of surgery (before midnight) by eliminating nausea and vomiting.

Timeline

Start: 2026-07
Primary completion: 2027-07
Completion: 2027-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aprepitant	Other / unclassified	32 mg	Intravenous
Background	Dexamethasone	Small molecule	4 mg	Intravenous
Background	Ondansetron	Other / unclassified	4 mg	Intravenous

Indications

No indication recorded.